Back to library
CognitiveSubcutaneous
DSIP
Also known as: Delta Sleep-Inducing Peptide · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Nonapeptide first isolated from rabbit cerebrospinal fluid during delta-wave sleep. Promotes delta-wave sleep, modulates corticotropic axis, and shows opioid-system interactions. Mechanism remains poorly characterized despite decades of research.
At a glance
- Half-life
- 18 minutes
- Common route
- Subcutaneous
- Typical dose range
- 100–750mcg
- Stability (reconstituted)
- 30days refrigerated
Best timing
30–60 minutes pre-bed. Short serum half-life; some users dose at lights-out for onset support.
Contraindications
- Pregnancy
- Active depression without supervision
- Limited modern human safety data
Watch symptoms
- Vivid dreams or nightmares in some users
- Mild dizziness or grogginess on waking
- Headache
- Inconsistent subjective sleep response — DSIP response is highly individual in published trials
Citations